LivaNova (LIVN) Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LivaNova in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" LIVN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LIVN, but not buy additional shares or sell existing shares.
View LIVN analyst ratings or view top-rated stocks.

6 brokers have issued 12-month price objectives for LivaNova's stock. Their LIVN share price forecasts range from $52.00 to $84.00. On average, they anticipate the company's share price to reach $65.00 in the next twelve months. This suggests a possible upside of 16.5% from the stock's current price.
View analysts price targets for LIVN or view top-rated stocks among Wall Street analysts.

LivaNova's stock was trading at $55.54 at the beginning of the year. Since then, LIVN shares have increased by 0.5% and is now trading at $55.79.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our LIVN earnings forecast.

LivaNova will be holding an earnings conference call on Wednesday, November 1st at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

LivaNova PLC (NASDAQ:LIVN) issued its quarterly earnings data on Wednesday, July, 26th. The company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.54 by $0.24. The business had revenue of $293.90 million for the quarter, compared to the consensus estimate of $265.05 million. LivaNova had a negative net margin of 8.94% and a positive trailing twelve-month return on equity of 11.60%. LivaNova's revenue for the quarter was up 15.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.53 EPS.

ETFs with the largest weight of LivaNova (NASDAQ:LIVN) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Invesco NASDAQ Future Gen 200 ETF (QQQS), IQ Healthy Hearts ETF (HART), Simplify Health Care ETF (PINK), Global X Aging Population ETF (AGNG), Invesco S&P MidCap 400 GARP ETF (EWMC) and iShares U.S. Medical Devices ETF (IHI).JPMorgan BetaBuilders U.S. Small Cap Equity ETF (BBSC).

LivaNova updated its FY23 earnings guidance on Wednesday, July, 26th. The company provided earnings per share (EPS) guidance of $2.55-$2.75 for the period, compared to the consensus earnings per share estimate of $2.59.

47 employees have rated LivaNova Chief Executive Officer Damien McDonald on Glassdoor.com. Damien McDonald has an approval rating of 77% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other LivaNova investors own include BioTelemetry (BEAT), Occidental Petroleum (OXY), Pfizer (PFE), Amarin (AMRN), Genocea Biosciences (GNCA), AbbVie (ABBV), Abbott Laboratories (ABT), ACADIA Pharmaceuticals (ACAD), Chipotle Mexican Grill (CMG) and CRISPR Therapeutics (CRSP).

LivaNova trades on the NASDAQ under the ticker symbol "LIVN."

LivaNova's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (13.51%), Alliancebernstein L.P. (4.13%), State Street Corp (3.69%), Hawk Ridge Capital Management LP (2.44%), Dimensional Fund Advisors LP (2.39%) and Geode Capital Management LLC (2.09%). Insiders that own company stock include Alfred J Novak, Damien Mcdonald, Daniel Jeffrey Moore and Marco Dolci.
View institutional ownership trends.

Shares of LIVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LIVN stock can currently be purchased for approximately $55.79.

LivaNova (NASDAQ:LIVN) has a market capitalization of $3.01 billion and generates $1.02 billion in revenue each year. The company earns $-86,250,000.00 in net income (profit) each year or ($1.82) on an earnings per share basis.

The company employs 2,900 workers across the globe.

LivaNova's mailing address is 20 EASTBOURNE TERRACE, LONDON X0, W2 6LG. The official website for the company is www.livanova.com. The company can be reached via phone at 442033250660, via email at investor.relations@livanova.com, or via fax at 281-218-9332.